The Alliance for Regenerative Medicine (ARM)
2099 Pennsylvania Avenue, NW
Washington
DC
20006
United States
Website: http://www.alliancerm.org/
Email: info@alliancerm.org
43 articles about The Alliance for Regenerative Medicine (ARM)
-
The Alliance for Regenerative Medicine predicts up to 17 cell and gene therapy approvals this year and defends high prices, while FDA’s Peter Marks expresses concern about manufacturing costs.
-
ARM and NIIMBL Release Project A-Cell To Bring Quality By Design Principles To Cell-Based Therapy Manufacturing
7/26/2022
The Alliance for Regenerative Medicine and the National Institute for Innovation in Manufacturing BioPharmaceuticals released Project A-Cell, a multistakeholder collaboration to incorporate Quality by Design principles into a manufacturing case study of a Chimeric Antigen Receptor T-cell therapy.
-
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
-
The Alliance for Regenerative Medicine Announces Election of 2022 Officers, Executive Committee, and Board of Directors
10/21/2021
The Alliance for Regenerative Medicine, the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies, announced the election of its 2022 Officers, Executive Committee, and Board of Directors.
-
Alliance for Regenerative Medicine Annual Report Highlights Record Sector Growth and Resilience in 2020
3/16/2021
Sector financing reached $19.9B in 2020, doubling from the previous year; 2021 is likely to be a record year for the number of regulatory decisions on new regenerative medicine products
-
The Alliance for Regenerative Medicine Announces Election of 2021 Officers, Executive Committee, and Board of Directors
10/21/2020
The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies, announced today the election of its 2021 Officers, Executive Committee, and Board of Directors. The Executive Committee and Board of Directors oversee the formation and execution of ARM’s strategic priorities and focus areas over the coming ye
-
New Report: Regenerative Medicine & Advanced Therapies Sector Thriving Despite COVID-19
8/6/2020
The Alliance for Regenerative Medicine announces the publication of its H1 2020 Global Sector Report, “Innovation in the Time of COVID-19.” The report provides an in-depth look at trends and metrics in the gene, cell, and tissue-based therapeutic sector in the midst of the pandemic.
-
The Alliance for Regenerative Medicine Announces 2020 Virtual Fly-In, Connecting Sector Stakeholders with Congressional Representatives Amidst the COVID-19 Pandemic
5/20/2020
The Alliance for Regenerative Medicine (ARM), the international advocacy organization for the cell and gene therapy and broader regenerative medicine sector, announced that it will be holding its annual Legislative Fly-In today. This event, which has been remodeled to take place virtually, enables ARM members to advocate on Capitol Hill for legislative support of gene and cellular therapies and other regenerative medicines.
-
The Alliance for Regenerative Medicine Releases 2019 Annual Report and Sector Year in Review
3/5/2020
Second highest year for global financings in regenerative medicine, with nearly $10 billion raised globally Washington, DC, March 05, 2020 .
-
The Alliance for Regenerative Medicine Releases Agenda for 2020 Cell & Gene Meeting on the Mediterranean
2/13/2020
The Alliance for Regenerative Medicine, the international advocacy organization representing the cell and gene therapy and broader regenerative medicine sector, released the agenda for its second annual Cell & Gene Meeting on the Mediterranean.
-
The Alliance for Regenerative Medicine Announces 2020 Cell & Gene Therapies State of the Industry Briefing
12/11/2019
The Alliance for Regenerative Medicine, the international advocacy organization representing the cell and gene therapy and broader regenerative medicine sector, announced its 2020 Cell & Gene Therapies State of the Industry briefing will take place January 13, 2020 in San Francisco, held in conjunction with Biotech Showcase™ 2020.
-
The Alliance for Regenerative Medicine Outlines Recommendations for Increasing the Number of European-Based ATMP Clinical Trials
10/31/2019
Europe has become less competitive than other regions in attracting new ATMP clinical trials.
-
The Alliance for Regenerative Medicine Releases Statement of Principles on Genome Editing
8/27/2019
The Alliance for Regenerative Medicine released a Therapeutic Developers’ Statement of Principles, setting forth a bioethical framework for the use of gene editing in therapeutic applications.
-
The Alliance for Regenerative Medicine, which calls itself an “international advocacy organization representing the cell and gene therapy and broader regenerative medicine sector,” issued a bioethical framework for gene editing’s use in therapeutic applications.
-
The Alliance for Regenerative Medicine Announces 2018 Cell & Gene Therapies State of the Industry Briefing
12/1/2017
The Alliance for Regenerative Medicine announced its 2018 Cell & Gene Therapies State of the Industry briefing will take place January 8, 2018 in San Francisco, held in conjunction with Biotech Showcase™ 2018.
-
The Alliance for Regenerative Medicine (ARM) Announces Election Of 2018 ARM Executive Committee And Board Of Directors
10/5/2017
-
The Alliance for Regenerative Medicine (ARM) Releases Q2 2017 Data Report, Highlighting Sector Trends And Metrics
8/18/2017
-
The Alliance for Regenerative Medicine (ARM) Announces Second Reimbursement And Market Access-Focused White Paper In Three-Part Series Published In In Vivo
7/24/2017
-
The Alliance for Regenerative Medicine (ARM) Publishes Position On Hospital Exemption Of Advanced Therapy Medicinal Products In Europe
2/17/2017
-
The Alliance for Regenerative Medicine (ARM) Releases Statement In Response To National Academies Report On Human Genome Editing
2/15/2017